




PHARMACEUTICAL 2019

RespireRx Pharmaceuticals Inc.
Rank 349 of 363





PHARMACEUTICAL 2019

RespireRx Pharmaceuticals Inc.
Rank 349 of 363

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 361% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 230% points.

The company's Economic Capital Ratio, given in the ranking table, is -416%, being 453% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	121
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,857
Liabilities, Non-Current	0
Other Assets	3.1
Other Compr. Net Income	0
Other Expenses	303
Other Liabilities	0
Other Net Income	-113
Other Revenues	0
Property and Equipment	0
Research and Development	688
Selling, General and Administrative Expense	1,488

Output Variable	Value in 1000 USD
Assets	124
Liabilities	5,857
Expenses	2,479
Revenues	0
Stockholders Equity	-5,733
Net Income	-2,592
Comprehensive Net Income	-2,592
Economic Capital Ratio	-416%